Details checkedClinical trial listing onlyCheckedregistry

Colorado LOOT clemastine plus engineered sound CAPD study

Also known as: Colorado LOOT Clemastine + Engineered Sound Study, CAPD-LOOT, Localized Oligodendrocyte Optimization Therapy, LOOT, Clemastine Fumarate Combined With Engineered Sound, NCT07304024

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 1/2

Status

Active

Target Gene

—

Route / Mode

Oral clemastine plus headphone-delivered engineered sound

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

United States

Population

adult, older-adult, age-related, central-auditory-processing-disorder, speech-in-noise, combination-study

Trial IDs

Mechanism

Clemastine fumarate combined with proprietary engineered sound stimulation, intended to drive remyelination of activated central auditory pathways for age-related central auditory processing disorder/hearing-in-noise deficits.

Indications

Hearing Loss Sensorineural Hearing Loss Age-Related Hearing Loss Noise-Induced Hearing Loss

Notes

Promoted from needs-review to a verified study-level record. The registry supports an active University of Colorado-led Phase 1/2a trial of clemastine plus engineered sound, but the engineered acoustic stimulus is proprietary and no standalone commercial product sponsor is disclosed.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT07304024, CAPD-LOOT, LOOT

Open

Key Events

2025-03-31

CAPD-LOOT clemastine plus engineered sound study started

2026-04-30

ClinicalTrials.gov update lists CAPD-LOOT as recruiting

Clinical Trials (1)